Guggenheim Capital LLC boosted its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 37.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 614,643 shares of the biopharmaceutical company’s stock after purchasing an additional 166,839 shares during the period. Guggenheim Capital LLC owned 0.28% of Alexion Pharmaceuticals worth $73,504,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also added to or reduced their stakes in ALXN. Amundi Pioneer Asset Management Inc. lifted its position in shares of Alexion Pharmaceuticals by 1,786.3% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 1,454,498 shares of the biopharmaceutical company’s stock valued at $173,944,000 after buying an additional 1,377,388 shares during the last quarter. Investec Asset Management LTD bought a new position in shares of Alexion Pharmaceuticals during the fourth quarter worth approximately $84,096,000. Alkeon Capital Management LLC bought a new position in shares of Alexion Pharmaceuticals during the third quarter worth approximately $70,145,000. Wells Fargo & Company MN increased its stake in shares of Alexion Pharmaceuticals by 32.7% during the third quarter. Wells Fargo & Company MN now owns 1,558,531 shares of the biopharmaceutical company’s stock worth $218,647,000 after purchasing an additional 383,713 shares during the period. Finally, Clearbridge Investments LLC increased its stake in shares of Alexion Pharmaceuticals by 9.5% during the fourth quarter. Clearbridge Investments LLC now owns 3,541,871 shares of the biopharmaceutical company’s stock worth $423,572,000 after purchasing an additional 307,117 shares during the period. 95.38% of the stock is owned by institutional investors.
In other Alexion Pharmaceuticals news, EVP John B. Moriarty sold 3,363 shares of Alexion Pharmaceuticals stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $115.70, for a total transaction of $389,099.10. Following the transaction, the executive vice president now directly owns 71,400 shares of the company’s stock, valued at approximately $8,260,980. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Ludwig Hantson sold 13,245 shares of Alexion Pharmaceuticals stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $116.31, for a total value of $1,540,525.95. Following the transaction, the chief executive officer now directly owns 131,425 shares in the company, valued at $15,286,041.75. The disclosure for this sale can be found here. Insiders have sold a total of 31,253 shares of company stock worth $3,656,229 over the last ninety days. Company insiders own 4.35% of the company’s stock.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.09 by $0.39. The firm had revenue of $909.70 million for the quarter, compared to the consensus estimate of $880.38 million. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.26 EPS. equities analysts anticipate that Alexion Pharmaceuticals, Inc. will post 6.12 earnings per share for the current fiscal year.
A number of equities analysts have recently weighed in on the company. Evercore ISI upgraded Alexion Pharmaceuticals from an “in-line” rating to an “outperform” rating in a research note on Monday, February 5th. Leerink Swann lowered their target price on Alexion Pharmaceuticals from $166.00 to $153.00 and set an “outperform” rating on the stock in a research note on Friday, February 9th. Raymond James Financial reiterated an “outperform” rating and set a $130.00 target price (down previously from $178.00) on shares of Alexion Pharmaceuticals in a research note on Thursday, January 4th. They noted that the move was a valuation call. Cowen reiterated a “buy” rating and set a $163.00 target price on shares of Alexion Pharmaceuticals in a research note on Friday. Finally, Robert W. Baird upgraded Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $150.00 price objective on the stock in a research note on Monday, December 18th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and twenty have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $154.64.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.